SecBot SecBot
PRESS-RELEASE ·Filed Jun 1, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 6/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The positive Part 1 safety data de-risks TLX591-Tx's combination profile and supports continued Phase 3 enrollment. Monitor FDA IND amendment decision and Part 2 enrollment updates as key catalysts. The differentiated liver-clearance mechanism could provide competitive advantage over existing PSMA RLTs if confirmed in larger randomized data.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$9.16
T+0 close · Jun 1, 2026 · via day close
Latest settled
+21.51%
T+60 · $11.13
Vs SPY
+20.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $9.16entry
  2. T+1 · 6mo ago −4.26%α −3.54% · $8.77
  3. T+5 · 5mo ago +2.73%α +5.69% · $9.41
  4. T+20 · 5mo ago +29.26%α +30.82% · $11.84
  5. T+60 · 3mo ago +21.51%α +20.39% · $11.13

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable tolerability with standard-of-care combinations and no new safety signals. The data support advancing to Part 2 randomized expansion, with FDA engagement underway for U.S. enrollment. This is a positive clinical milestone for a first-in-class rADC candidate, but the stock impact is tempered by early-stage data and no near-term approval catalyst.

Key Facts

  • Part 1 data from 36 patients showed acceptable safety across all SoC combination cohorts (abiraterone, enzalutamide, docetaxel) with no new safety signals.
  • All 36 patients received both doses of TLX591-Tx per protocol; hematologic events (Grade 3-4 thrombocytopenia/neutropenia) were transient and consistent with class profile.
  • Dosimetry showed radiation exposure to key organs well below established safety limits; highest absorbed dose in liver (1.62-5.08 mGy/MBq), low salivary gland uptake (0.001-0.104 mGy/MBq).
  • Part 2 randomized 2:1 expansion is actively dosing in Australia, New Zealand, Canada, Turkey, UK, with approvals in China, Singapore, South Korea; FDA engagement underway for U.S. IND amendment.
  • TLX591-Tx is a first-in-class lutetium rADC with differentiated pharmacology (liver clearance, minimal kidney/salivary toxicity) vs. existing PSMA-targeted small molecule RLTs.

Financial Impact

No financial data provided; TLX591-Tx has not received marketing authorization in any jurisdiction.

pipeline valueregulatory milestones

Risk Factors

  • Part 2 randomized data (n~490) may not replicate Part 1 safety profile or show efficacy benefit vs. SoC alone.
  • Regulatory delays in U.S. IND amendment could slow enrollment and timeline.
  • Competition from approved PSMA-targeted RLTs (e.g., Pluvicto) with established commercial presence.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3304754

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +21.24% at T+60 after the May 18, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026